3rd World ADC Asia 2020

3rd World ADC Asia 2020

Online, Japan
7 - 9 December 2020
46 days until the conference begins

Important Dates

Abstract Submission Deadline
6th December 2020

About 3rd World ADC Asia 2020

Maximizing the Clinical Therapeutic Index of ADCs The only conference in Asia to specifically focus on antibody-drug conjugate drug development


Drug development, Medicine, Health, Pharmaceuticals

Call for Papers

World ADC Asia prides itself in being the only dedicated conference that unites the leaders in the antibody-drug conjugate field to identify and discuss the critical factors that will influence the next 12 months of your ADC development. This conference was designed with the leaders from, Daiichi Sankyo, Eisai, Shanghai Miracogen and Immunowork, and it has an agenda that addresses the biggest challenges, latest data, science and lessons learned from the last year of ADC drug development.

Across 3 days, with 100+ ADC experts, this comprehensive antibody-drug conjugate conference will enable you to propel your ADC pipeline into clinical development. Some of the highlights from the 2020 meeting include exploring targets beyond HER-2; confidently meeting Chinese NMPA regulatory requirements to successfully translate into the clinic and effectively scaling up your manufacturing processes for clinical development. World ADC Asia not only delves into general antibody-drug conjugate challenges, it also focuses on challenges and opportunities specific to development within Asia.

With partnerships being a huge factor in providing momentum of ADC drug development in Asia, this is your perfect opportunity to gain critical insight and valuable partnerships to accelerate the development of your ADC drug pipeline.

Don't miss your opportunity to:

* Hear the rationale for submitting INDs in different countries; how to leverage the strength of Asia and US/Europe with the NMPA, BlissBio and Shanghai Miracogen

* Form lasting connections by engaging directly with 100+ attendees from the leading companies actively developing ADCs in Asia, such as Daiichi Sankyo, Bio-Thera, Sumitomo Dainippon Pharma Co, Seattle Genetics and Mersana

* Learn from the leading Chinese biotech's who have recently submitted INDs or entered the clinic including Shanghai Miracogen, Blissbio and Genequantum

Time: 08:00 to 18:00

Speakers: Alex Xu, NMPA, Amy Han, Regeneron, Atsushi Suwa, Sumitomo Dainippon Pharma Co, Bruce Han, New Bio Tx, Cristina Von Burlow, AstraZeneca, Daejin Abidoye, Seattle Genetics, Daisuke Okajima, Daiichi Sankyo, Gang Qin, Genequantum, George Badescu, Heidelburg Pharma, Greg Thurber, University of Michigan, Hui Lu, Levena Biopharma, Jia He, Beacon Targeted Therapies, Jinwon Jung, ABL Bio, Jeiwook Chae, LegoChem Biosciences, Kenji Iida, Daiichi Sankyo, John Lambert, Immunogen, Junho Chung, Seoul National University College of Medicine, Ling Xu, Mersana, Mary Hu, Miracogen, Michael Chen, Merck Sereno - Beijing, Rick Powers, Independent Consultant, Robert Zhao, Hangzhou DAC Biotech, Sang Jeon Chung, Sungkyunkwan University, Scott Wheelwright, Bio-Thera Solutions Ltd, Tse Wen Chang, Immunwork, Ziping Wei, Bliss Bio, Xinfang Li, Mabplex

Prices: Drug Developer and Platform Tech - Conference Only: USD 1799.00, Drug Developer and Platform Tech - Workshop Only: USD 399.00, Small Biotech - Conference Only: USD 1399.00, Small Biotech - Workshop Only: USD 349.00, Vendor - Conference Only: USD 2599.00

Keep Up to Date with PaperCrowd

Sign up and follow your favorite conferences.

We are no longer accepting conference submissions on PaperCrowd. We apologise for any inconvenience.